The lncRNA DRAIC/PCAT29 locus constitutes a tumor-suppressive nexus

Molecular Cancer Research

Volumn 13, Issue 5, 2015, Pages 828-838

  Sakurai, Kouhei ^a   Reon, Brian J ^a   Anaya, Jordan ^a   Dutta, Anindya ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; LONG NONCODING RNA DRAIC; LONG NONCODING RNA PCAT29; LONG UNTRANSLATED RNA; UNCLASSIFIED DRUG; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BLADDER CANCER; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 15Q; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; GENE INDUCTION; GENE REPRESSION; GLIOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MELANOMA; METASTASIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; RNA SEQUENCE; STOMACH ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; PROSTATIC NEOPLASMS; RNA, LONG NONCODING; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84939564622     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0016-T     Document Type: Article

References (36)

1. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32:5501-11.
2. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
3. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-74.
4. Negishi M, Wongpalee SP, Sarkar S, Park J, Lee KY, Shibata Y, et al. A new lncRNA, APTR, associates with and represses the CDKN1A/p21 promoter by recruiting polycomb proteins. PLoS ONE 2014;9:e95216.
5. Dey BK, Pfeifer K, Dutta A. The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. Genes Dev 2014;28:491-501.
6. Mueller AC, Cichewicz MA, Dey BK, Layer R, Reon BJ, Gagan JR, et al. MUNC: a lncRNA that induces the expression of pro-myogenic genes in skeletal myogenesis. Mol Cell Biol 2015;35:498-513.
7. Kumar P, Anaya J, Mudunuri SB, Dutta A.Meta-analysis of tRNA derived RNA fragments reveals that they are evolutionarily conserved and associate with AGO proteins to recognize specific RNA targets. BMC Biol 2014;12:78
8. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011;147:358-69.
9. Yuan J, Yang F, Wang F, Ma J, Guo Y, Tao Q, et al. A long noncoding RNA activated by TGF-b promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014;25:666-81.
10. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov 2013;12:433-46.
11. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013;500:598-602.
12. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 2014;74:1651-60.
13. Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, et al. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res 2014;12:1081-7.
14. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011;71:1313-24.
15. Sun D, Layer R, Mueller AC, Cichewicz MA, Negishi M, Paschal BM, et al. Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene 2014;33:1448-57.
16. Mueller AC, Sun D, Dutta A. The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene 2013;32:1164-72.
17. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
18. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2011;18:11-22.
19. Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RG, McConkey D, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
20. Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensivemolecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
21. Decker KF, Zheng D, He Y, Bowman T, Edwards JR, Jia L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res 2012;40: 10765-79.
22. Tewari AK, Yardimci GG, Shibata Y, Sheffield NC, Song L, Taylor BS, et al. Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. Genome Biol 2012;13:R88.
23. Thalmann GN, Anezinis PE, Chang S, Thaimann N, Hopwood VL, Pathak S, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer model of human prostate cancer. Cancer Res 1994;54:2577-81.
24. Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature 2013;493:231-5.
25. Rajan P, Sudbery IM, Villasevil MEM, Mui E, Fleming J, Davis M, et al. Nextgeneration sequencing of advanced prostate cancer treated with androgendeprivation therapy. Eur Urol 2014;66:32-9.
26. Yu J, Yu J, Mani R-S, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443-54.
27. Tan PY, Chang CW, Chng KR, Wansa KDSA, Sung W-K, Cheung E. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol 2012;32:399-414.
28. Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep 2014;9:1618-27.
29. Robinson JLL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, et al. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. Oncogene 2014;33: 5666-74.
30. Jin H-J, Zhao JC, Wu L, Kim J, Yu J. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun 2014;5:3972.
31. Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer 2014;14:187-98.
32. Jin H-J, Zhao JC, Ogden I, Bergan RC, Yu J. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res 2013;73:3725-36.
33. BowenC, Bubendorf L, Voeller HJ, Progression T, Slack R, Willi N, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111-5.
34. Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, et al. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol 2012;180: 848-61.
35. Xu LL, Srikantan V, Sesterhenn IA, Augustus M, Dean R, Moul JW, et al. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol 2000;163:972-9.
36. Dey BK, Mueller AC, Dutta A. Long non-coding RNA as emerging regulators of differentiation, development, and disease. Transcription 2014;5:e944014.